Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 472

1.

"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".

Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R.

Alzheimers Dement. 2019 Jan;15(1):153-157. doi: 10.1016/j.jalz.2018.11.002. No abstract available.

PMID:
30642435
2.

Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease.

Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM.

Sci Transl Med. 2019 Jan 9;11(474). pii: eaau6550. doi: 10.1126/scitranslmed.aau6550.

PMID:
30626715
3.

Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.

Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertürk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C.

Nat Neurosci. 2019 Jan 7. doi: 10.1038/s41593-018-0296-9. [Epub ahead of print]

PMID:
30617257
4.

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.

Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C.

JAMA Neurol. 2019 Jan 7. doi: 10.1001/jamaneurol.2018.4249. [Epub ahead of print]

PMID:
30615028
5.

Obstructive sleep apnea treatment, slow wave activity, and amyloid-β.

Ju YS, Zangrilli MA, Finn MB, Fagan AM, Holtzman DM.

Ann Neurol. 2018 Dec 31. doi: 10.1002/ana.25408. [Epub ahead of print]

PMID:
30597615
6.

New insights into the role of TREM2 in Alzheimer's disease.

Gratuze M, Leyns CEG, Holtzman DM.

Mol Neurodegener. 2018 Dec 20;13(1):66. doi: 10.1186/s13024-018-0298-9. Review.

7.

Amyloid-β 'seeds' in old vials of growth hormone.

Huynh TV, Holtzman DM.

Nature. 2018 Dec;564(7736):354-355. doi: 10.1038/d41586-018-07604-6. No abstract available.

PMID:
30546137
8.

Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2018;66(3):1213-1221. doi: 10.3233/JAD-180564.

9.

High-affinity interactions and signal transduction between Aβ oligomers and TREM2.

Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, Colonna M, Golde TE.

EMBO Mol Med. 2018 Nov;10(11). pii: e9027. doi: 10.15252/emmm.201809027.

10.

Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.

Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV.

Mol Neurodegener. 2018 Oct 19;13(1):57. doi: 10.1186/s13024-018-0286-0.

11.

Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC.

Brain. 2018 Nov 1;141(11):3233-3248. doi: 10.1093/brain/awy244.

PMID:
30304397
12.

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.

McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.

PMID:
30217935
13.

Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Shi Y, Holtzman DM.

Nat Rev Immunol. 2018 Dec;18(12):759-772. doi: 10.1038/s41577-018-0051-1. Review.

PMID:
30140051
14.

In Search of an Identity for Amyloid Plaques.

Huynh TV, Holtzman DM.

Trends Neurosci. 2018 Aug;41(8):483-486. doi: 10.1016/j.tins.2018.06.002.

PMID:
30053949
15.

Intercellular Spread of Protein Aggregates in Neurodegenerative Disease.

Davis AA, Leyns CEG, Holtzman DM.

Annu Rev Cell Dev Biol. 2018 Oct 6;34:545-568. doi: 10.1146/annurev-cellbio-100617-062636. Epub 2018 Jul 25.

PMID:
30044648
16.

Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP.

Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chávez-Gutiérrez L, Cleverley K, Noy S, Sheppard O, Collins T, Powell C, Sarell CJ, Rickman M, Choong X, Tosh JL, Siganporia C, Whittaker HT, Stewart F, Szaruga M; London Down syndrome consortium , Murphy MP, Blennow K, de Strooper B, Zetterberg H, Bannerman D, Holtzman DM, Tybulewicz VLJ, Fisher EMC.

Brain. 2018 Jun 26. doi: 10.1093/brain/awy159. [Epub ahead of print]

17.

Using the A/T/N Framework to Examine Driving in Preclinical AD.

Roe CM, Babulal GM, Stout SH, Ott BR, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC.

Geriatrics (Basel). 2018 Jun;3(2). pii: 23. doi: 10.3390/geriatrics3020023. Epub 2018 May 2. No abstract available.

PMID:
29805967
18.

AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.

Hettinger JC, Lee H, Bu G, Holtzman DM, Cirrito JR.

Mol Neurodegener. 2018 May 15;13(1):22. doi: 10.1186/s13024-018-0256-6.

19.

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.

Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

PLoS One. 2018 May 9;13(5):e0195838. doi: 10.1371/journal.pone.0195838. eCollection 2018.

20.

Dual therapy for Aβ amyloidosis in AD: A successful one-two combo.

Patel TK, Holtzman DM.

J Exp Med. 2018 May 7;215(5):1267-1268. doi: 10.1084/jem.20180494. Epub 2018 Apr 23.

21.

Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype.

Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA.

Brain. 2018 Jun 1;141(6):1828-1839. doi: 10.1093/brain/awy103.

PMID:
29672664
22.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors.

Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.

23.

Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.

Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, Henne K, Leyns CE, Gallardo G, Ulrich JD, Sullivan PM, Lerner EP, Hudry E, Sweeney ZK, Dennis MS, Hyman BT, Watts RJ, Holtzman DM.

J Clin Invest. 2018 May 1;128(5):2144-2155. doi: 10.1172/JCI96429. Epub 2018 Mar 30.

24.

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease.

Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM; ADNI.

Alzheimers Dement. 2018 Jul;14(7):869-879. doi: 10.1016/j.jalz.2018.01.012. Epub 2018 Mar 23.

25.

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.

Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM.

Alzheimers Dement. 2018 Nov;14(11):1460-1469. doi: 10.1016/j.jalz.2018.01.013. Epub 2018 Mar 2.

26.

ApoE facilitates the microglial response to amyloid plaque pathology.

Ulrich JD, Ulland TK, Mahan TE, Nyström S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M, Holtzman DM.

J Exp Med. 2018 Apr 2;215(4):1047-1058. doi: 10.1084/jem.20171265. Epub 2018 Feb 26.

27.

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Lancet Neurol. 2018 Mar;17(3):241-250. doi: 10.1016/S1474-4422(18)30028-0. Epub 2018 Feb 1.

PMID:
29397305
28.

Regulation of amyloid-β dynamics and pathology by the circadian clock.

Kress GJ, Liao F, Dimitry J, Cedeno MR, FitzGerald GA, Holtzman DM, Musiek ES.

J Exp Med. 2018 Apr 2;215(4):1059-1068. doi: 10.1084/jem.20172347. Epub 2018 Jan 30.

29.

Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.

Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YS.

JAMA Neurol. 2018 May 1;75(5):582-590. doi: 10.1001/jamaneurol.2017.4719.

PMID:
29379963
30.

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM.

Nat Rev Neurol. 2018 Mar;14(3):168-181. doi: 10.1038/nrneurol.2017.185. Epub 2018 Jan 29. Review.

31.

Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers.

Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM.

Alzheimers Dement. 2018 May;14(5):610-616. doi: 10.1016/j.jalz.2017.11.011. Epub 2018 Jan 10.

PMID:
29328928
32.

Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis.

Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, Stewart FR, Mahan TE, Ulrich JD, Cole T, Holtzman DM.

Neuron. 2017 Dec 6;96(5):1013-1023.e4. doi: 10.1016/j.neuron.2017.11.014.

33.

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, Budur K, Florian H, Mendonca N, Holtzman DM.

J Prev Alzheimers Dis. 2017;4(4):236-241. doi: 10.14283/jpad.2017.36.

PMID:
29181488
34.

Pretreatment with Human Chorionic Gonadotropin Protects the Neonatal Brain against the Effects of Hypoxic-Ischemic Injury.

Movsas TZ, Weiner RL, Greenberg MB, Holtzman DM, Galindo R.

Front Pediatr. 2017 Nov 3;5:232. doi: 10.3389/fped.2017.00232. eCollection 2017.

35.

Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.

Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, Carmichael ST, Dickinson SL, Dickson DW, Emr M, Fillit H, Greenberg SM, Hutton ML, Knopman DS, Manly JJ, Marder KS, Moy CS, Phelps CH, Scott PA, Seeley WW, Sieber BA, Silverberg NB, Sutherland ML, Taylor A, Torborg CL, Waddy SP, Gubitz AK, Holtzman DM.

Neurology. 2017 Dec 5;89(23):2381-2391. doi: 10.1212/WNL.0000000000004717. Epub 2017 Nov 8. Review.

36.

Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.

Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, Buggia-Prévot V, De Rossi P, Vetrivel KS, Lamb R, Argemi A, Allaert ES, Rathbun EM, Krause SV, Wagner SL, Parent AT, Holtzman DM, Thinakaran G.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9665-E9674. doi: 10.1073/pnas.1708568114. Epub 2017 Oct 23.

37.

TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy.

Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11524-11529. doi: 10.1073/pnas.1710311114. Epub 2017 Oct 9.

38.

NMNAT3 is protective against the effects of neonatal cerebral hypoxia-ischemia.

Galindo R, Banks Greenberg M, Araki T, Sasaki Y, Mehta N, Milbrandt J, Holtzman DM.

Ann Clin Transl Neurol. 2017 Aug 30;4(10):722-738. doi: 10.1002/acn3.450. eCollection 2017 Oct.

39.

Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal.

Kang SS, Kurti A, Baker KE, Liu CC, Colonna M, Ulrich JD, Holtzman DM, Bu G, Fryer JD.

Hum Mol Genet. 2018 Jan 15;27(2):211-223. doi: 10.1093/hmg/ddx366.

40.

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.

Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C; Alzheimer’s Disease Neuroimaging Initiative, Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM.

Nature. 2017 Sep 28;549(7673):523-527. doi: 10.1038/nature24016. Epub 2017 Sep 20.

41.

Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms.

Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Deming Y, Kapoor M, Tosto G, Mayeux RP, Holtzman DM, Fagan AM, Morris JC, Bateman RJ, Goate AM; Dominantly Inherited Alzheimer Network (DIAN); Disease Neuroimaging Initiative (ADNI); NIA-LOAD family study, Harari O.

Alzheimers Dement. 2018 Feb;14(2):205-214. doi: 10.1016/j.jalz.2017.08.013. Epub 2017 Sep 21.

PMID:
28943286
42.

The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.

Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O.

Immunity. 2017 Sep 19;47(3):566-581.e9. doi: 10.1016/j.immuni.2017.08.008.

43.

Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.

Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JAHR, Holtzman DM.

Brain. 2017 Aug 1;140(8):2104-2111. doi: 10.1093/brain/awx148.

44.

TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.

Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, Loginicheva E, Gilfillan S, Cella M, Virgin HW, Unanue ER, Wang Y, Artyomov MN, Holtzman DM, Colonna M.

Cell. 2017 Aug 10;170(4):649-663.e13. doi: 10.1016/j.cell.2017.07.023.

45.

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.

Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ.

Alzheimers Dement. 2017 Aug;13(8):841-849. doi: 10.1016/j.jalz.2017.06.2266. Epub 2017 Jul 19. Erratum in: Alzheimers Dement. 2017 Oct;13(10 ):1185.

46.

Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.

Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM.

Alzheimers Dement. 2018 Jan;14(1):62-70. doi: 10.1016/j.jalz.2017.06.2264. Epub 2017 Jul 12. Erratum in: Alzheimers Dement. 2018 Aug;14(8):1100.

47.

Glial contributions to neurodegeneration in tauopathies.

Leyns CEG, Holtzman DM.

Mol Neurodegener. 2017 Jun 29;12(1):50. doi: 10.1186/s13024-017-0192-x. Review.

48.

Correction: AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.

Ising C, Gallardo G, Leyns CEG, Wong CH, Jiang H, Stewart F, Koscal LJ, Roh J, Robinson GO, Serrano JR, Holtzman DM.

J Exp Med. 2017 Jul 3;214(7):2163. doi: 10.1084/jem.2016212505192017c. Epub 2017 May 23. No abstract available.

49.

Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease.

Schindler SE, Jasielec MS, Weng H, Hassenstab JJ, Grober E, McCue LM, Morris JC, Holtzman DM, Xiong C, Fagan AM.

Neurobiol Aging. 2017 Aug;56:25-32. doi: 10.1016/j.neurobiolaging.2017.04.004. Epub 2017 Apr 14.

50.

Diurnal oscillation of CSF Aβ and other AD biomarkers.

Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ.

Mol Neurodegener. 2017 May 8;12(1):36. doi: 10.1186/s13024-017-0161-4.

Supplemental Content

Loading ...
Support Center